StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 0.5 %

Shares of AKTX stock opened at $3.27 on Friday. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40. The company has a 50 day moving average price of $3.61 and a 200 day moving average price of $2.56.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.